Gene Therapy for Malignant Mesothelioma

[1]  A. Melcher,et al.  A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. , 1997, Human gene therapy.

[2]  J. Coll,et al.  Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments , 1997, Gene Therapy.

[3]  B. Robinson,et al.  The induction of immune responses to murine malignant mesothelioma by IL‐2 gene transfer , 1997, Immunology and cell biology.

[4]  S. Steinberg,et al.  Simian virus-40 large-T antigen binds p53 in human mesotheliomas , 1997, Nature Medicine.

[5]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[6]  A. Kinsella,et al.  The role of the bystander effect in suicide gene therapy. , 1997, European journal of cancer.

[7]  R. Vile,et al.  Generation of an anti‐tumour immune response in a non‐immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1‐like profile of intratumoural cytokine expression , 1997, International journal of cancer.

[8]  D. Lowrie,et al.  In vivo gene therapy of malignant tumours with heat shock protein-65 gene , 1997, Gene Therapy.

[9]  A. Bout,et al.  Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene , 1997, Gene Therapy.

[10]  R. Ramesh,et al.  Immune system in suicide-gene therapy , 1997, The Lancet.

[11]  J. Wilson,et al.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.

[12]  J. Wilson,et al.  Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. , 1996, Human gene therapy.

[13]  J. Wilson,et al.  Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). , 1996, Human gene therapy.

[14]  G. Viale,et al.  Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.

[15]  M. Black,et al.  Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. O’Malley,et al.  Combination gene therapy for oral cancer in a murine model. , 1996, Cancer research.

[17]  J. Olsen,et al.  Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. , 1996, Cancer research.

[18]  H. Hwang,et al.  Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. , 1996, Human gene therapy.

[19]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Fishman,et al.  Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. , 1996, Gene therapy.

[21]  P. Vogt,et al.  The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. , 1996, Pathology, research and practice.

[22]  A. Eggermont,et al.  Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. , 1995, British Journal of Cancer.

[23]  B. Davidson,et al.  Treatment of Experimental Human Mesothelioma Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase Gene , 1995, Annals of surgery.

[24]  H. Hwang,et al.  Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. , 1995, American journal of respiratory cell and molecular biology.

[25]  J. Koziol,et al.  Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. , 1995, Human gene therapy.

[26]  X. -. Chen,et al.  Combination gene therapy for liver metastasis of colon carcinoma in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Moolten Fl.  Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994 .

[28]  R. Vile,et al.  Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. , 1994, Cancer research.

[29]  R. Grossman,et al.  Adenovirus‐mediated gene therapy of experimental gliomas , 1994, Journal of neuroscience research.

[30]  J. Douillard,et al.  Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma , 1994, Cancer.

[31]  C. Richards,et al.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Tiberghien.  Use of suicide genes in gene therapy , 1994, Journal of leukocyte biology.

[33]  J. Pilewski,et al.  Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. , 1994, The Annals of thoracic surgery.

[34]  B. Davidson,et al.  Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. , 1994, Cancer research.

[35]  R. Grossman,et al.  Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Freeman,et al.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.

[37]  R. Vile,et al.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. , 1993, Cancer research.

[38]  D. Klatzmann,et al.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Wilson,et al.  Gene therapy: adenovirus vectors. , 1993, Current opinion in genetics & development.

[40]  T. Kawabe,et al.  Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors. , 1993, American journal of respiratory cell and molecular biology.

[41]  C. Cicala,et al.  SV40 induces mesotheliomas in hamsters. , 1993, The American journal of pathology.

[42]  V. Rusch.  Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. , 1993, Chest.

[43]  A. Musk,et al.  Interleukin-2 and Lymphokine-Activated Killer-Cells in Malignant Mesothelioma , 1993 .

[44]  P. Astoul,et al.  Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. , 1993, Chest.

[45]  Z. Ram,et al.  In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer research.

[46]  J. Wells,et al.  Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. , 1992, Cancer letters.

[47]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[48]  F. Varlet,et al.  Activity of intrapleural recombinant gamma‐interferon in malignant mesothelioma , 1991, Cancer.

[49]  V. Rusch,et al.  Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  R. Boehme,et al.  Antiviral activity and mechanism of action of ganciclovir. , 1988, Reviews of infectious diseases.

[51]  A. Ardizzoni,et al.  Intrapleural natural beta interferon in the treatment of malignant pleural effusions. , 1988, Oncology.